These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645 [TBL] [Abstract][Full Text] [Related]
4. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476 [TBL] [Abstract][Full Text] [Related]
5. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724 [TBL] [Abstract][Full Text] [Related]
6. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647 [TBL] [Abstract][Full Text] [Related]
7. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Raizer JJ J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112 [TBL] [Abstract][Full Text] [Related]
8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968 [TBL] [Abstract][Full Text] [Related]
10. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Wu M; Yuan Y; Pan YY; Zhang Y Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891 [TBL] [Abstract][Full Text] [Related]
11. Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells. Jin HO; Hong SE; Kim CS; Park JA; Kim JH; Kim JY; Kim B; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK Toxicol Appl Pharmacol; 2015 Aug; 287(1):17-25. PubMed ID: 25981168 [TBL] [Abstract][Full Text] [Related]
12. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374 [TBL] [Abstract][Full Text] [Related]
13. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. Andersson U; Johansson D; Behnam-Motlagh P; Johansson M; Malmer B Acta Oncol; 2007; 46(7):951-60. PubMed ID: 17917826 [TBL] [Abstract][Full Text] [Related]
14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
15. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011 [TBL] [Abstract][Full Text] [Related]
16. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157 [TBL] [Abstract][Full Text] [Related]
17. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Liu H; Li L; Li XQ; Liu XJ; Zhen YS Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999 [TBL] [Abstract][Full Text] [Related]
18. Case-specific potentiation of glioblastoma drugs by pterostilbene. Schmidt L; Baskaran S; Johansson P; Padhan N; Matuszewski D; Green LC; Elfineh L; Wee S; Häggblad M; Martens U; Westermark B; Forsberg-Nilsson K; Uhrbom L; Claesson-Welsh L; Andäng M; Sintorn IM; Lundgren B; Lönnstedt I; Krona C; Nelander S Oncotarget; 2016 Nov; 7(45):73200-73215. PubMed ID: 27689322 [TBL] [Abstract][Full Text] [Related]
19. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related]
20. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]